002287 奇正藏药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,471,75518.10%2,045,1522,044,7891,770,4861,485,059
减:营业总成本1,166,22221.84%1,628,6741,555,9731,374,8251,109,398
    其中:营业成本270,92039.02%323,315324,140265,342214,795
               财务费用42,42913.36%50,22939,92219,476(22,305)
               资产减值损失(242)-530.09%(1,401)(2,454)(16,061)--
公允价值变动收益68,212134.89%37,074(3,429)20,693--
投资收益10,696-75.78%28,780(33,652)305,89312,659
    其中:对联营企业和合营企业的投资收益(4,483)-128.74%1,888(54,907)293,3612,109
营业利润450,5708.61%646,383521,541790,206455,607
利润总额441,4376.85%644,413519,202787,914444,963
减:所得税费用47,06940.13%65,23549,56077,08840,785
净利润394,3683.91%579,178469,643710,826404,178
减:非控股权益992-203.03%(2,021)(2,900)(5,050)217
股东净利润393,3763.38%581,199472,542715,876403,961

市场价值指针
每股收益 (元) *0.7423.33%1.0970.8921.3540.764
每股派息 (元) *----0.4800.3900.5900.340
每股净资产 (元) *7.02710.34%6.7646.0395.7234.683
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容